Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified
A study in human monocyte-derived microglia and human brain tissue slices suggests that inflammatory brain conditions, including traumatic brain injury and neurodegenerative diseases such as Alzheimer's disease, could be treated using an existing drug candidate targeting P2X7R. The post Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified appeared first on…
Researchers from the University of Birmingham have identified an existing anti-inflammatory drug that could potentially treat Alzheimer's disease, traumatic brain injury (TBI), and other neurodegenerative conditions. Experiments using human brain cells and tissue slices demonstrated that blocking the P2X7 receptor, which initiates inflammatory signaling, reduces the release of pro-inflammatory cytokines.
This finding suggests that targeting the P2X7 receptor could provide a new therapeutic approach for various chronic neurological disorders, including TBI, neurodegenerative diseases, and psychiatric conditions like depression and psychosis. The researchers developed a method to transform human peripheral monocytes into microglia-like cells, which allowed them to study the impact of P2X7 receptor antagonists on microglial activity.
They found that these antagonists effectively curbed pro-inflammatory cytokine release in human microglia, providing direct evidence for the use of P2X7R antagonism to inhibit microglia-mediated inflammation. The study's findings could pave the way for the development of clinical trials to evaluate the efficacy of P2X7R antagonists in patients with neurodegenerative conditions and TBI, where current pharmacological treatments are lacking.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
